Treatment with glecaprevir/pibrentasvir (G/P) demonstrated a virologic response at post-treatment week 12, which was superior to the prior efficacy threshold.
Lana Pine
Advertisement
Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at [email protected].
Articles by Lana Pine
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Cases of Cyclosporiasis Continue to Rise Across 31 States With Michigan Reporting Highest Numbers
2
Cyclosporiasis: When to Seek Medical Care, Duration of Illness, and Preventive Measures
3
New Single-Step Test Nearly Doubles Early Lyme Disease Detection
4